Nat Cell Biol:发现促进癌症转移的关键蛋白质

2014-09-26 佚名 不详

想知道癌细胞如何转移嘛?近日,刊登在国际杂志Nature Cell Biology上的一篇研究论文中,来自德克萨斯大学癌症研究中心的研究人员通过研究表示,癌细胞可以适应一定的能量需求来进行扩散转移,癌症发生转移是引发癌症相关死亡的主要原因,揭示癌症转移的机理对于开发新型抗癌疗法非常关键。 研究者发现,癌细胞可以通过其“定居”的部位获取不同的能量来继续其转移活动,在研究过程中研究人员发现了一种

想知道癌细胞如何转移嘛?近日,刊登在国际杂志Nature Cell Biology上的一篇研究论文中,来自德克萨斯大学癌症研究中心的研究人员通过研究表示,癌细胞可以适应一定的能量需求来进行扩散转移,癌症发生转移是引发癌症相关死亡的主要原因,揭示癌症转移的机理对于开发新型抗癌疗法非常关键。

研究者发现,癌细胞可以通过其“定居”的部位获取不同的能量来继续其转移活动,在研究过程中研究人员发现了一种名为PGC-1α的蛋白质,其是一种对细胞代谢调节异常重要的转录激活子,对于癌细胞获取能量得以生存和扩散也至关重要。

Valerie LeBleu博士说道,开发新型的疗法主要集中于对癌细胞代谢的弱点进行攻击,因此确定扩散中的癌细胞的代谢需求就显得非常有意义,在癌细胞扩散到另一个位点过程中研究人员发现扩散中的癌细胞依赖于线粒体;癌细胞可以利用PGC-1α来刺激新生线粒体的生长,而线粒体作为细胞的能量工厂也为细胞提供源源不断的能量,当然癌细胞的转移同时也依赖于PGC-1α相关的一个过程,该过程名为氧化磷酸化,其可以在癌细胞扩散期间刺激ATP的产生。

如果线粒体是厨房的话,PGC-1α就是大厨师,而ATP就是氧化磷酸化的关键组分。当某些癌细胞可以“旅行”至机体别的位点时,仍会有一部分癌细胞留存在“老巢”繁殖生长,如果有一种疗法可以阻断癌细胞的迁移,那么抑制PGC-1α或许就有可能帮助抑制癌症转移。

最后研究者表示,我们都知道癌细胞非常喜欢转移寻找新家,本文研究揭示了乳腺癌患者中,侵袭性癌细胞中PGC-1α的表达和癌症远端转移产生的相关性,为后期开发新型抗癌疗法提供了新的线索和帮助。

原始出处

LeBleu VS1, O'Connell JT2, Gonzalez Herrera KN3, Wikman H4, Pantel K4, Haigis MC3, de Carvalho FM5, Damascena A5, Domingos Chinen LT5, Rocha RM5, Asara JM6, Kalluri R1.PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis.Nat Cell Biol. 2014 Sep 21

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
    2014-12-14 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
    2015-03-27 维他命
  7. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
    2015-06-08 sunylz
  8. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1766899, encodeId=952f1e66899c2, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Tue Jun 30 06:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765532, encodeId=e50a1e6553211, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Oct 28 00:52:00 CST 2014, time=2014-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027602, encodeId=6ab9202e602ee, content=<a href='/topic/show?id=fd08301865e' target=_blank style='color:#2F92EE;'>#关键蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30186, encryptionId=fd08301865e, topicName=关键蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Sat Jul 25 10:52:00 CST 2015, time=2015-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880290, encodeId=c30918802905e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Dec 14 18:52:00 CST 2014, time=2014-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868906, encodeId=6e4b186890679, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Aug 16 05:52:00 CST 2015, time=2015-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959151, encodeId=626219591518d, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 27 11:52:00 CST 2015, time=2015-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917076, encodeId=541c191e07620, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jun 08 14:52:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296895, encodeId=c4d51296895f3, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1379078, encodeId=1a3c13e90787c, content=<a href='/topic/show?id=e185e14882c' target=_blank style='color:#2F92EE;'>#癌症转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71488, encryptionId=e185e14882c, topicName=癌症转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=50ba440, createdName=xirongguo, createdTime=Sun Sep 28 00:52:00 CST 2014, time=2014-09-28, status=1, ipAttribution=)]

相关资讯

PNAS:阻断癌症转移的新策略

血道转移是癌症在体内扩散最常见的方式之一。来自康奈尔大学生物医学工程系的研究人员在一项新研究中提出,血液有可能是阻止癌症转移最理想的位点。这项研究工作发表在近期的《美国科学院院刊》(PNAS)杂志上。 癌细胞从身体的一个部位转移至非相邻位点,会大大降低患者的生存概率——相比于治疗单个位点的肿瘤,针对转移性癌症的治疗往往更具侵袭性,付出的代价也更大。一直以来肿瘤学家们都

PNAS:绘制癌转移的发展史

肿瘤能够通过转移扩散到机体的其他部分,但人们对这一过程并不十分了解。此前,研究者们一直难以确定转移发生在原发瘤发育的什么阶段,或者特定转移瘤是否直接来自于原发瘤。现在,科学家们开发了一个简单的新方法,能够快速分析患者体内多个肿瘤位点之间的进化关系,为制定合适的治疗方案提供宝贵信息。 “构建患者体内所有肿瘤的‘家谱’,不仅可以帮助我们确定肿瘤之间的差异,还有助于了解肿瘤的发展史,”文章的通讯作

Cell:揪出癌症盔甲的薄弱环节

来自约翰霍普金斯大学的细胞生物学家们发现了一种独特的乳腺癌细胞类型,证实其导致了癌症侵袭到周围组织中。由于侵袭是致命的癌症转移过程的第一步,研究人员说他们或许已经找到了癌症盔甲的薄弱环节以及有可能的治疗新靶点。他们的研究结果在线发表在12月12日的《细胞》(Cell)杂志上。 约翰霍普金斯大学医学院细胞生物学助理教授Andrew Ewald博士说:“转移是乳腺癌患者面

Nature:癌细胞的“糖衣炮弹”信号

细胞的细胞膜是细胞与外界环境交换信息的一个信号界面,这一结构由脂质和蛋白组成,后者包含有跨膜蛋白和脂质蛋白,通过共价键进一步修饰,添加糖能形成糖蛋白。癌细胞比健康细胞糖蛋白的水平更高,如mucin-1,个别糖蛋白还可以传递环境信号,直接促进恶性肿瘤发生。糖蛋白也能相互组织,形成糖萼(glycocalyx)。近期在这一方面,来自康奈尔大学的研究人员发现了这种包被在细胞膜上的蛋白的物理特征是如何调控细

抗疟疾药物氯奎宁或可有效抑制癌症的侵袭转移

近日,来自法兰德斯大学联办生物技术研究院的研究人员在对实验动物进行研究时发现,抗疟疾药物氯奎宁或具有明显的抗癌效应,截至目前,研究者们推测氯喹可以增加癌细胞对化疗的敏感性。研究者表示,氯奎宁同样可以使得肿瘤组织的异常血管正常化,结果从一方面来讲会增加癌细胞的屏障功能,进而阻断癌细胞的扩散和转移;从另一方面将则会增强肿瘤的灌注,使得其对化疗作用更为敏感。 氯奎宁是一种常见的用于治疗疟疾及